1. Home
  2. ANIX vs WYY Comparison

ANIX vs WYY Comparison

Compare ANIX & WYY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

HOLD

Current Price

$3.52

Market Cap

108.5M

Sector

Health Care

ML Signal

HOLD

Logo WidePoint Corporation

WYY

WidePoint Corporation

HOLD

Current Price

$10.13

Market Cap

107.8M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANIX
WYY
Founded
1982
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
108.5M
107.8M
IPO Year
2013
2005

Fundamental Metrics

Financial Performance
Metric
ANIX
WYY
Price
$3.52
$10.13
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
3
Target Price
$8.67
$8.67
AVG Volume (30 Days)
300.9K
236.6K
Earning Date
05-27-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
12.82
N/A
EPS
N/A
0.01
Revenue
$210,000.00
$150,545,364.00
Revenue This Year
N/A
$14.41
Revenue Next Year
N/A
$11.41
P/E Ratio
N/A
$1,070.00
Revenue Growth
N/A
5.59
52 Week Low
$2.32
$2.80
52 Week High
$5.46
$24.30

Technical Indicators

Market Signals
Indicator
ANIX
WYY
Relative Strength Index (RSI) 58.95 36.02
Support Level $2.48 $4.59
Resistance Level $3.53 $10.49
Average True Range (ATR) 0.29 0.98
MACD 0.01 -0.42
Stochastic Oscillator 59.13 9.62

Price Performance

Historical Comparison
ANIX
WYY

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

About WYY WidePoint Corporation

WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and an Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically, the company generates a majority of its revenue from the United States and the rest from Europe.

Share on Social Networks: